|
注册号: Registration number: |
ChiCTR1800017652 |
|
最近更新日期: Date of Last Refreshed on: |
2018-08-08 17:18:06 |
|
注册时间: Date of Registration: |
2018-08-08 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
中国胃食管反流病患者夜间症状治疗现状 多中心、前瞻性临床观察项目 |
|
Public title: |
Multi-centre, prospective and observational study for treatment of Chinese patients with GERD night-time symptoms |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中国胃食管反流病患者夜间症状治疗现状 多中心、前瞻性临床观察项目 |
|
Scientific title: |
Multi-centre, prospective and observational study for treatment of Chinese patients with GERD night-time symptoms |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王英俊 |
研究负责人: |
王邦茂 |
|
Applicant: |
Yingjun Wang |
Study leader: |
Bangmao Wang |
|
申请注册联系人电话: Applicant telephone: |
+86 13811565821 |
研究负责人电话:
Study leader's |
+86 13602007150 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
441598934@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
gi.tmuh@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国北京市朝阳区西大望路甲12号(国家广告产业园区)2号楼2层20473 |
研究负责人通讯地址: |
中国天津市和平区鞍山道154号 |
|
Applicant address: |
Room 20473, F2, 2nd Building, 12 Dawang Road West, Chaoyang District, Beijing, China |
Study leader's address: |
154 Anshan Road, Heping District, Tianjin, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
吉护(北京)健康咨询有限公司 |
||
|
Applicant's institution: |
Beijing JiHu health consulting co. LTD |
||
|
研究负责人所在单位: |
天津医科大学总医院 |
||
|
Affiliation of the Leader: |
Tianjin Medical University General Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
IRB2017-113-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
天津医科大学总医院医学伦理委员会 |
||
|
Name of the ethic committee: |
The Medical Ethic Committee of Tianjin Medical University General Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-26 00:00:00 | ||
|
伦理委员会联系人: |
金东来 |
||
|
Contact Name of the ethic committee: |
Donglai Jin |
||
|
伦理委员会联系地址: |
天津医科大学总医院, 天津市和平区鞍山道154号 |
||
|
Contact Address of the ethic committee: |
Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, Tianjin, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
天津医科大学总医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Tianjin Medical University General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
天津市和平区鞍山道154号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
154 Anshan Road, Heping District, Tianjin, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中国医疗保健国际交流促进会 |
||||||||||||||||||||||
|
Source(s) of funding: |
China International Exchange and Promotive Association for Medical and Health Care |
||||||||||||||||||||||
|
研究疾病: |
胃食管反流病 |
||||||||||||||||||||||
|
Target disease: |
Gastroesophageal Reflux Disease(GERD) |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
病因学/相关因素研究 |
||||||||||||||||||||||
|
Study type: |
Cause/Relative factors study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
探讨我国胃食管反流病伴夜间症状患者接受不同治疗方案的临床疗效和依从性 |
||||||||||||||||||||||
|
Objectives of Study: |
Primary: Clinical efficacy: to compare the improvement of night-time symptoms and sleep quality of GERG patients following 1, 2 and 4 weeks of receiving different treatment regimens. Secondary: compliance: to compare the proportion of good patients compliance in completed treatment on various treatment programme. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1、年龄小于18岁或大于65岁 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Non-GERD or referral GERD patients; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2017-08-01 00:00:00至 To 2018-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2017-08-01 00:00:00 至 To 2018-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
请联系研究员 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Please contact the researcher |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRRF表为电子扫描件 EDC为excel格式 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRFs are scanned copies EDC are managed as excel document |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |